Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial. Issue 1 (5th April 2022)

• Record Type: Journal Article
• Authors: Muangpaisan, Weerasak; Wiputhanuphongs, Puvanant; Jaisupa, Nattapon; Junnu, Sarawut; Samer, Jutima; Moongkarndi, Primchanien; Supapueng, Orawan; Chalermsri, Chalobol; Neungton, Neelobol
• Is Part Of: Alzheimer's & dementia. Volume 8:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-05
• Subjects: Alzheimer's disease -- clinical trial -- cognition -- Garcinia mangostana -- mangosteen extract -- older adults -- oxidative stress -- safety; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1002/trc2.12292
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: The water‐soluble mangosteen pericarp extract's (WME) effect was investigated in Alzheimer's disease (AD). Methods: The participants received 4 mg/kg/day of WME for 24 weeks (low dose, n = 33), 4 mg/kg/day for 12 weeks and then 8 mg/kg/day for 12 weeks (high dose, n = 33); or a placebo (n = 42). The outcomes were neuropsychiatric test scores, safety, tolerability, and the blood 4‐hydroxynonenal level. Results: The proportion of participants who achieved the minimum clinically important difference for the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog; –2.6 points) at 24 weeks was significantly higher in the low‐dose group (and a trend in the high‐dose group) than in the placebo group. WME appeared safe and well tolerated. At 24 weeks, the 4‐hydroxynonenal level declined in both intervention groups. The participants with a 5% reduction in this level showed greater ADAS‐Cog improvements. Conclusion: WME is a safe and well‐tolerated cognitive enhancer in AD with varying benefits across individuals based on antioxidative response.